


Baseline characteristics of SELECT trial participants

N=17,605

Male or female



HbA_{1c} (%), mean



5.78%

SD 0.34

Prediabetes: 64%

Race: n (%)




Asian	1,447 (8.2)
Black	671 (3.8)
White	14,791 (84.0)
Other	527 (3.0)

HbA_{1c}, glycated haemoglobin; SD, standard deviation; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.

Baseline characteristics of SELECT trial participants

N=17,605



BMI, body mass index; eGFR, estimated glomerular filtration rate; RI, renal impairment; SD, standard deviation; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.

Baseline characteristics of SELECT trial participants

N=17,605



MI only

n=11,908

67.6%



Stroke only

n=3,135

17.8%




PAD only

n=777

4.4%

≥2 CV inclusion criteria: n=1,433, 8.1%



Baseline characteristics of SELECT trial participants

N=17,605

High-sensitivity C-reactive protein, (mg/L), median (IQR)	1.83 (0.87–4.12)
---	------------------

Pulse (beats/min), mean (SD)	68.8 (10.7)
------------------------------	-------------

Lipids, (mg/dL), median (IQR)	
Total Cholesterol:	153.5 (131.1–182.9)
LDL-C:	78.1 (60.7–102.1)
HDL-C:	43.7 (37.1–51.8)
Triglycerides:	134.6 (98.3–187.8)

Blood Pressure, (mmHg), mean (SD)	
Systolic BP:	131.0 (15.4)
Diastolic BP:	79.3 (10.0)

IQR, interquartile range; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; BP, blood pressure.
SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity.
Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.

Baseline characteristics of SELECT trial participants

N=17,605



Subclass, n (%)

HFrEF:	2,268 (12.9)
HFpEF:	1,341 (7.6)
Unknown:	662 (3.8)

NYHA class, n (%)

NYHA class I:	1,368 (7.8)
NYHA class II:	2,534 (14.4)
NYHA class III:	362 (2.1)
Unknown:	10 (<0.1)

Obesity-related comorbidities, n (%)

CKD:	1,947 (11.1)
Knee osteoarthritis:	2,849 (16.2)
Hip osteoarthritis:	1,323 (7.5)
NAFL:	1,451 (8.2)
NASH:	115 (0.7)
Sleep apnoea:	2,542 (14.4)
Asthma:	1,187 (6.7)
COPD:	1,466 (8.3)
Gout:	1,532 (8.7)

CHF, chronic heart failure; CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NAFL, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NYHA, New York Heart Association; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.

Baseline characteristics of SELECT trial participants

Concomitant CV-related medications

	Overall N=17,605		Overall N=17,605
Anti-hypertensive medications, n (%)	16,168 (91.8)	Diuretics, n (%)	5,861 (33.3)
Beta blockers	12,329 (70.0)	Loop diuretics	2,207 (12.5)
ACE inhibitors	7,915 (45.0)	Thiazides	2,010 (11.4)
Angiotensin receptor blockers	5,259 (29.9)	Aldosterone antagonists	1,808 (10.3)
Calcium channel blockers	4,706 (26.7)	Thiazide-like diuretics	1,014 (5.8)
Angiotensin receptor-neprilysin inhibitor	254 (1.4)	Platelet aggregation inhibitors, n (%)	15,130 (85.9)
Lipid-lowering drugs, n (%)	15,804 (89.8)	Acetylsalicylic acid	13,691 (77.8)
Statins	15,369 (87.3)	P2Y12 inhibitors	5,912 (33.6)
Ezetimibe	2,314 (13.1)	Anticoagulant medications, n (%)	2,220 (12.6)
Fibrates	477 (2.7)	DOAC	1,510 (8.6)
PCSK-9 inhibitors	335 (1.9)	Vitamin K antagonists	670 (3.8)
		Anti-angina agents, n (%)	3,487 (19.8)
		Anti-arrhythmic agents, n (%)	584 (3.3)

CV, cardiovascular; PCSK-9, Proprotein convertase subtilisin/kexin type 9; DOAC, Direct oral anticoagulants.
 SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity.
 Lingvay I et al. *Obesity (Silver Spring)* 2023;31:111–22.